At the 44th Annual J.P. Morgan Healthcare Conference, CEO Michael Farrell underscored ResMed’s transformation over the past five years, navigating COVID-19 challenges and supply-chain headwinds. He noted the company’s 36-year evolution from a spin-out of Baxter—acquired for AUD 1.2 million—into a global leader with a market capitalization near USD 37 billion. Over the trailing twelve months, ResMed delivered USD 5.3 billion in revenue with non-GAAP gross margins above 60% and operating margins surpassing 33%. Farrell highlighted investments in digital health platforms and cloud-connected devices as key drivers of recurring revenue and patient engagement improvements.

ResMed’s first quarter saw revenue rise 9.1% year-over-year to USD 1.34 billion, marginally above consensus estimates. Earnings per share reached USD 2.55, outpacing forecasts by USD 0.06 and reflecting a net margin of 27.35%. Return on equity improved to 25.45%, driven by disciplined cost management and a higher mix of software-enabled solutions. Management reaffirmed full-year guidance for mid-single-digit revenue growth and non-GAAP EPS in the range of USD 9.40 to USD 9.60, citing robust demand in North America and accelerating adoption of mask-less ventilation therapies in Europe and Asia-Pacific.

In early January, Director Peter Farrell sold 2,000 shares—reducing his stake by 2.91%—and CEO Michael Farrell disposed of approximately 4,991 shares. Combined transactions generated proceeds near USD 0.75 million. Although both executives retain significant ownership positions, the disclosures prompted heightened investor attention on insider activity. ResMed maintains a conservative capital allocation policy, with a dividend payout ratio around 25% and a debt-to-equity ratio under 0.10, indicating ample flexibility for buybacks or strategic acquisitions.

Following the quarter, research firms lifted several price targets, with average forecasts rising toward USD 296.00. Zacks Research incrementally raised FY2026–FY2028 EPS projections to USD 10.62, USD 11.20 and USD 12.80, respectively, reflecting stronger margin outlooks. Morgan Stanley and RBC have reiterated outperform ratings, while nine other brokerages maintain buy recommendations. Institutional investors have increased positions: Norges Bank initiated a new stake, Goldman Sachs added over 58,000 shares in Q1, and Jones Financial expanded its holding by more than 50%, underscoring broad confidence among long-term holders.